Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.

Inclusion Criteria: Those who meet all the selected standards below can enter the group test: * The subject can communicate well with the researchers and understand and comply with the various items in this study, understand and sign the consent of informed consent; * 18-65 years old (including the boundary value), and men and women are not limited (calculated based on the date of signing the consent of informedness); * Serum virus standard: serum HBSAG positive for more than 6 months or more than 6 months chronic Evidence of HBV infection. * No obvious liver cirrhosis is judged by researchers; Those who have been treated after treatment need to meet the following conditions: * The subject must receive oral nucleoside (acid) drug treatment before screening ≥6 months and the stable treatment plan before the screening period is ≥3 months; * Historian history records of the HBV DNA \